Literature DB >> 17072707

The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.

Alex Cahana1, Alexandre Mauron.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17072707     DOI： 10.1007/s00540-006-0432-7

Source DB:  PubMed          Journal:  J Anesth        ISSN： 0913-8668            Impact factor:   2.078


× No keyword cloud information.
  8 in total

1.  Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Authors:  Peter Jüni; Anne W S Rutjes; Paul A Dieppe
Journal:  BMJ       Date:  2002-06-01

2.  A coxib a day won't keep the doctor away.

Authors:  Eric J Topol; Gary W Falk
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

3.  Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib.

Authors:  M J James; L G Cleland
Journal:  J Med Ethics       Date:  2004-04       Impact factor: 2.903

4.  Failing the public health--rofecoxib, Merck, and the FDA.

Authors:  Eric J Topol
Journal:  N Engl J Med       Date:  2004-10-06       Impact factor: 91.245

5.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

6.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

Authors:  Peter Jüni; Linda Nartey; Stephan Reichenbach; Rebekka Sterchi; Paul A Dieppe; Matthias Egger
Journal:  Lancet       Date:  2004 Dec 4-10       Impact factor: 79.321

7.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

8.  What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2002-06-25       Impact factor: 8.262
  8 in total
  3 in total

1.  Nuremberg code turns 60.

Authors:  Michel Thieren; Alexandre Mauron
Journal:  Bull World Health Organ       Date:  2007-08       Impact factor: 9.408

2.  Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studies.

Authors:  Włodzimierz Matysiak; Barbara Jodłowska-Jedrych
Journal:  Protoplasma       Date:  2010-08-19       Impact factor: 3.356

3.  Exploiting Injury-Induced Peripheral Opioid Receptor Changes in Novel Analgesic Development for Chronic Pain.

Authors:  Craig T Hartrick
Journal:  Front Pain Res (Lausanne)       Date:  2022-04-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.